WO2026052046 - USE OF ANTI-CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATE FOR TREATING GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
National phase entry is expected:
Publication Number
WO/2026/052046
Publication Date
12.03.2026
International Application No.
PCT/CN2025/119274
International Filing Date
05.09.2025
Title **
[English]
USE OF ANTI-CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATE FOR TREATING GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
[French]
UTILISATION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-CLAUDINE 18.2 POUR LE TRAITEMENT DU CANCER GASTRIQUE ET/OU DE L'ADÉNOCARCINOME DE LA JONCTION GASTRO-ŒSOPHAGIENNE
[Chinese]
抗Claudin18.2抗体药物偶联物用于治疗胃癌和/或胃食管结合部腺癌的用途
Applicants **
REMEGEN CO., LTD.
Inventors
FANG, Jianmin
SU, Xiaohong
WANG, Yan
Priority Data
202411251892.2
06.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1779 | |
| EPO | Filing, Examination, Granting | 12570 | |
| Japan | Filing, Examination, Granting | 2215 | |
| South Korea | Filing, Examination, Granting | 2265 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,569
Contact Us
Abstract[English]
Disclosed are a method for treating and preventing cancer, and compositions and uses related thereto. Specifically, provided is a method for treating cancer by means of administering a certain dose of a pharmaceutical composition comprising an anti-Claudin 18.2 antibody-drug conjugate to a subject. The method possesses remarkable efficacy and safety.[French]
L'invention concerne une méthode de traitement et de prévention du cancer, ainsi que des compositions et des utilisations associées. Plus particulièrement, l'invention concerne une méthode de traitement du cancer par administration d'une certaine dose d'une composition pharmaceutique comprenant un conjugué anticorps-médicament anti-Claudine 18.2 à un sujet. La méthode présente une efficacité et une sécurité remarquables.[Chinese]
一种用于治疗和预防癌症的方法，以及与之相关的组合物和用途，具体提供了一种通过向个体施用一定剂量的包含抗Claudin18.2抗体药物偶联物的药物组合物治疗癌症的方法，该方法具有显著的有效性和安全性。